Adaptimmune Therapeutics (FRA:473A) 3-Year Book Growth Rate : -57.10% (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics 3-Year Book Growth Rate?

Adaptimmune Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was €0.09.

During the past 12 months, Adaptimmune Therapeutics's average Book Value per Share Growth Rate was -81.20% per year. During the past 3 years, the average Book Value per Share Growth Rate was -57.10% per year. During the past 5 years, the average Book Value per Share Growth Rate was -36.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 12 years, the highest 3-Year average Book Value per Share Growth Rate of Adaptimmune Therapeutics was 612.10% per year. The lowest was -57.10% per year. And the median was -17.70% per year.

Competitive Comparison of Adaptimmune Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Adaptimmune Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptimmune Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Adaptimmune Therapeutics's 3-Year Book Growth Rate falls into.

Adaptimmune Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Adaptimmune Therapeutics (FRA:473A) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Adaptimmune Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics (FRA:473A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (FRA:473A) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

ADAP:USA

Address

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.adaptimmune.com

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

Adaptimmune Therapeutics (FRA:473A) Headlines

No Headlines